Special Issue

Antibody Drug and Target Discovery for Cancer Therapies

Message from the Guest Editor

Antibodies are a class of biological therapeutics that is quickly expanding with now more than 100 antibodies approved by the FDA. All of these drugs bind extracellular or transmembrane targets and most of them inhibit their target function by blocking receptor-ligand interactions. However, therapeutic antibodies are not limited to canonical antibodies and other avenues such as antibody-drug conjugate (ADC) or bispecific antibodies in oncoimmunology are exciting possibilities for cancer therapies. In the future, intracellular antibodies—i.e., expressed within the cells—may have a huge impact on cancer treatments once their delivery will be efficient for inhibiting intracellular targets in clinic.

This Special Issue of Antibodies aims to provide an up-to-date overview of therapeutic antibodies but also of the use of antibodies (or fragment antibodies) for discovering novel therapeutic targets of interest (either extra or intracellular ones) or novel inhibitory mechanisms and their validation. In this Special Issue, original research articles and reviews are welcome and should cover the aforementioned topics applied to cancer therapies.

Guest Editor

Dr. Nicolas Bery
Centre de Recherches en Cancérologie de Toulouse (CRCT), U1037 INSERM, Université Toulouse III, U5071 CNRS, 31100 Toulouse, France

Deadline for manuscript submissions

closed (20 October 2022)

Antibodies

an Open Access Journal by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed

mdpi.com/si/100426

Antibodies
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

mdpi.com/journal/antibodies

Antibodies

an Open Access Journal by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed

mdpi.com/journal/antibodies

MDPI

About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra
Institute of Biological Chemistry, Technical University Munich, Emil-Erlenmeyer-Forum 5, 85350 Freising-Weihenstephan, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Drug Discovery)